tiprankstipranks
Trending News
More News >
Novabay Pharmaceuticals (NBY)
:NBY
Advertisement

NovaBay Pharma (NBY) Price & Analysis

Compare
757 Followers

NBY Stock Chart & Stats

$1.30
-$0.04(-5.41%)
At close: 4:00 PM EST
$1.30
-$0.04(-5.41%)

Bulls Say, Bears Say

Bulls Say
Asset SaleNovaBay accepted an increased offer of $11.5 million for its Avenova assets, which may benefit the company's financial position.
Business StrategyThe sale of DERMAdoctor should reduce its cash burn and allows it to focus on pursuing newer and stronger growth opportunities that are better aligned with its core eyecare business.
Bears Say
Financial PerformanceNet loss was $1.6 million or EPS of $(1.37) compared with our estimates of $(1.28) and consensus of $(1.23).
Investor UncertaintyThe company did not provide 2024 guidance, which creates uncertainty for investors.
Revenue PerformanceRevenue was $2.4 million compared with our estimates of $2.8 million and consensus of $3.2 million.

NovaBay Pharma News

NBY FAQ

What was Novabay Pharmaceuticals’s price range in the past 12 months?
Novabay Pharmaceuticals lowest stock price was $0.46 and its highest was $4.44 in the past 12 months.
    What is Novabay Pharmaceuticals’s market cap?
    Novabay Pharmaceuticals’s market cap is $7.81M.
      When is Novabay Pharmaceuticals’s upcoming earnings report date?
      Novabay Pharmaceuticals’s upcoming earnings report date is Nov 06, 2025 which is in 16 days.
        How were Novabay Pharmaceuticals’s earnings last quarter?
        Novabay Pharmaceuticals released its earnings results on Aug 07, 2025. The company reported -$0.33 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.33.
          Is Novabay Pharmaceuticals overvalued?
          According to Wall Street analysts Novabay Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Novabay Pharmaceuticals pay dividends?
            Novabay Pharmaceuticals pays a Notavailable dividend of $0.8 which represents an annual dividend yield of N/A. See more information on Novabay Pharmaceuticals dividends here
              What is Novabay Pharmaceuticals’s EPS estimate?
              Novabay Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does Novabay Pharmaceuticals have?
              Novabay Pharmaceuticals has 6,010,749 shares outstanding.
                What happened to Novabay Pharmaceuticals’s price movement after its last earnings report?
                Novabay Pharmaceuticals reported an EPS of -$0.33 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.564%.
                  Which hedge fund is a major shareholder of Novabay Pharmaceuticals?
                  Currently, no hedge funds are holding shares in NBY

                  Company Description

                  Novabay Pharmaceuticals

                  NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through retailers, digital beauty channels, and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

                  NovaBay Pharma (NBY) Earnings & Revenues

                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Soligenix
                  Jaguar Animal Health
                  Evaxion Biotech
                  SciSparc Ltd.
                  60 Degrees Pharmaceuticals, Inc.

                  Ownership Overview

                  16.50%0.59%<0.01%81.93%
                  16.50% Insiders
                  <0.01% Other Institutional Investors
                  81.93% Public Companies and
                  Individual Investors

                  Options Prices

                  Currently, No data available
                  ---
                  Popular Stocks
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis